Stock Markets

FTSE 100 rises as investors cheer easing US recession fears


  • Admiral gains after H1 profit beat, special dividend
  • Industrial metal miners lag as heavyweights go ex-div
  • FTSE 100 up 0.8%, FTSE 250 adds 0.7%

Aug 15 (Reuters) – Britain’s equity indexes rose on Thursday as global markets cheered data that allayed concerns of a recession in the United States, while the UK economy grew in line with expectations.

The blue-chip FTSE 100 (.FTSE), opens new tab closed 0.8% higher and the midcap FTSE 250 (.FTMC), opens new tab added 0.7%, both rising for a fifth consecutive session.
Britain’s economy grew 0.6% in the second quarter of 2024, building on a rapid 0.7% recovery in the first quarter of the year after a shallow recession in the second half of 2023.

The pound rose 0.3% against the U.S. dollar, but money markets trimmed bets on the Bank of England cutting rates by 25 basis points in September to a 33% chance from 40% on Wednesday.

Benign U.S. consumer inflation data overnight had reinforced bets for the Federal Reserve to start cutting interest rates next month, while weekly jobless claims dropped to a one month low last week and retail sales increased by the most in nearly 1-1/2 years in July.

“The data has really helped to put to rest market participants’ concerns about a potential U.S. recession,” said Michael Brown, senior research strategist at Pepperstone.

Non-life insurers (.FTNMX303020), opens new tab were the top sectoral gainers with motor and home insurer Admiral Group (ADML.L), opens new tab up 6.5% after posting a forecast-beating 32% rise in pre-tax profit for the first half of 2024 and saying it would pay a special dividend.
Industrial metal miners (.FTNMX551020), opens new tab were among the worst performers, clocking up losses for a third session as Rio Tinto (RIO.L), opens new tab and Anglo American (AAL.L), opens new tab traded ex-dividend, or without entitlement to their latest payouts.
Index heavyweight AstraZeneca (AZN.L), opens new tab rose 2% after the U.S. Food and Drug Administration (FDA) granted its blockbuster cancer drug Imfinzi a priority review for patients with limited-stage small cell lung cancer in the United States.

Sign up here.

Reporting by Shubham Batra and Roshan Abraham in Bengaluru; Editing by Eileen Soreng, Kirsten Donovan

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Purchase Licensing Rights



Source link

Leave a Reply